Department of Biological Sciences, KAIST, 335 Gwahak-ro, Yuseong-gu, Daejeon, South Korea.
Biotherapeutics Translational Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), 125 Gwahak-ro, Yuseong-gu, Daejeon, South Korea.
Appl Microbiol Biotechnol. 2018 Jun;102(11):4729-4739. doi: 10.1007/s00253-018-8977-6. Epub 2018 Apr 13.
Despite the relatively low transfection efficiency and low specific foreign protein productivity (q) of Chinese hamster ovary (CHO) cell-based transient gene expression (TGE) systems, TGE-based recombinant protein production technology predominantly employs CHO cells for pre-clinical research and development purposes. To improve TGE in CHO cells, Epstein-Barr virus nuclear antigen-1 (EBNA-1)/polyoma virus large T antigen (PyLT)-co-amplified recombinant CHO (rCHO) cells stably expressing EBNA-1 and PyLT were established using dihydrofolate reductase/methotrexate-mediated gene amplification. The level of transiently expressed Fc-fusion protein was significantly higher in the EBNA-1/PyLT-co-amplified pools compared to control cultures. Increased Fc-fusion protein production by EBNA-1/PyLT-co-amplification resulted from a higher q attributable to EBNA-1 but not PyLT expression. The q for TGE-based production with EBNA-1/PyLT-co-amplified rCHO cells (EP-amp-20) was approximately 22.9-fold that of the control culture with CHO-DG44 cells. Rather than improved transfection efficiency, this cell line demonstrated increased levels of mRNA expression and replicated DNA, contributing to an increased q. Furthermore, there was no significant difference in N-glycan profiles in Fc-fusion proteins produced in the TGE system. Taken together, these results showed that the use of rCHO cells with co-amplified expression of the viral elements EBNA-1 and PyLT improves TGE-based therapeutic protein production dramatically. Therefore, EBNA-1/PyLT-co-amplified rCHO cells will likely be useful as host cells in CHO cell-based TGE systems.
尽管基于中国仓鼠卵巢(CHO)细胞的瞬时基因表达(TGE)系统的转染效率相对较低,且特定外源蛋白的产率(q)较低,但基于 TGE 的重组蛋白生产技术主要仍采用 CHO 细胞用于临床前研究和开发目的。为了提高 CHO 细胞中的 TGE,我们使用二氢叶酸还原酶/甲氨蝶呤介导的基因扩增,建立了稳定表达 EBNA-1 和 PyLT 的 EBV 核抗原-1(EBNA-1)/多瘤病毒大 T 抗原(PyLT)共扩增重组 CHO(rCHO)细胞。与对照培养物相比,EBNA-1/PyLT 共扩增池中转瞬表达的 Fc 融合蛋白水平显著更高。EBNA-1/PyLT 共扩增导致 Fc 融合蛋白产量增加,这归因于 EBNA-1 表达而不是 PyLT 表达。与对照培养物 CHO-DG44 细胞相比,基于 TGE 的 EBNA-1/PyLT 共扩增 rCHO 细胞(EP-amp-20)的 TGE 生产 q 值增加了约 22.9 倍。与提高转染效率不同,该细胞系表现出更高水平的 mRNA 表达和复制 DNA,从而提高了 q 值。此外,在 TGE 系统中产生的 Fc 融合蛋白的 N-糖基化谱没有显著差异。总之,这些结果表明,使用共扩增表达病毒元件 EBNA-1 和 PyLT 的 rCHO 细胞可显著提高基于 TGE 的治疗性蛋白生产。因此,EBNA-1/PyLT 共扩增 rCHO 细胞有望成为 CHO 细胞基于 TGE 的宿主细胞。